AAPG Shares Bounce Ahead of ASCO, Investors Eye Drug Results
Ascentage Pharma Group International’s U.S. shares climbed going into the long weekend, after the cancer drug maker put out fresh clinical results before the American Society of Clinical Oncology meeting. That offered investors an update on a pipeline that’s faced pressure most of the past year. The American depositary shares finished at $21.01 on Friday, gaining 35 cents, or 1.69%. The ADSs stayed far from the 52-week high of $48.45, though the stock had dropped to $18.56 earlier in the week.